A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID-19, AND PARTICIPANTS ≥65 YEARS OF AGE

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2026
This article has no abstract
Epistemonikos ID: 99216e6666ba88f8906f032cf8c9b61a699a8d8a
First added on: Sep 29, 2026